Therapeutic application of intrabodies against age-related neurodegenerative disorders

Current Pharmaceutical Design

Volumn 20, Issue 38, 2014, Pages 6028-6036

  Cardinale, Alessio ^a   Merlo, Daniela ^a,b   Giunchedi, Paolo ^c   Biocca, Silvia ^d  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Gene delivery; Intrabody; Nanotechnology; Neurodegenerative diseases; ScFv

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; MEMBRANE PROTEIN;

ADENO ASSOCIATED VIRUS; ADENOVIRIDAE; AGING; ALZHEIMER DISEASE; ARTICLE; HUMAN; IN VIVO GENE TRANSFER; LENTIVIRINAE; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROVIRUS; RISK FACTOR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE TRANSFER; GENETICS; INTRACELLULAR FLUID; METABOLISM; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROTEIN FOLDING; TRENDS;

AGING; ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; INTRACELLULAR FLUID; MEMBRANE PROTEINS; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING;

EID: 84923629903     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140314121444     Document Type: Article

References (104)

1. Chiti F, Dobson CM. Protein misfolding, functional amyloid and human disease. Annu. Rev. Biochem 2006; 75: 333-66.
2. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009; 8: 1056-72.
3. Lista S, Garaci FG, Toschi N, Hampel H. Imaging Epigenetics in Alzheimer's Disease. Curr Pharm Des 2013; Feb 13. [Epub ahead of print].
4. Habibi E, Masoudi-Nejad A, Abdolmaleky HM, Haggarty SJ. Emerging roles of epigenetic mechanisms in Parkinson's disease. Funct Integr Genomics 2011; 11: 523-37.
5. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003; 4: 49-60.
6. Hardy J, Revesz T. The spread of neurodegenerative disease. N Engl J Med 2012; 366: 2126-8.
7. Walker LC, Levine H 3rd, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci 2006; 8: 438-43.
8. Biocca S, Neuberger MS, Cattaneo A. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J 1990; 9: 101-8.
9. Biocca S, Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol 1995; 5: 248-52.
10. Cattaneo A, Biocca S. Intracellular Antibodies: development and applications. Berlin and Heidelberg: Springer-Verlag 1997.
11. Cardinale A and Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med 2008; 14: 373-80.
12. Cardinale A, Filesi I, Mattei S, Biocca S. Intracellular targeting and functional analysis of single-chain Fv fragments in mammalian cells. Methods 2004; 34: 171-8.
13. Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mithocondria. Bio/Technology 1995; 13: 1110-5.
14. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 1998; 60: 1489-96.
15. Chesnut JD, Baytan AR, Russell M, et al. Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody. J Immunol Methods 1996; 193: 17-27.
16. Dupont E, Prochiantz A, Joliot A. Identification of a signal peptide for unconventional secretion. J Biol Chem 2007; 282: 8994-9000.
17. Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci Lett 2009; 459: 16-8.
18. Butler DC, Messer A. Bifunctional anti-huntingtin proteasomedirected intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 2011; 6: e29199.
19. Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs 2001; 4. [Epub ahead of print].
20. rd. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. ProcNatlAcadSci USA 2005; 102: 8293-8.
21. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-8.
22. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009; 198: 157-74.
23. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9: 129-34.
24. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 3: 1105-16.
25. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology (N Y) 1994; 12: 396-9.
26. Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 1998; 17: 2445-56.
27. Griffin H, Elston R, Jackson D, et al. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 2006; 355: 360-78.
28. Tanaka T, Williams RL, Rabbitts TH. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007; 26: 3250-9.
29. Van den Abbeele A, De Clercq S, De Ganck A, et al. A llamaderived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell Mol Life Sci 2010; 67: 1519-35.
30. Lener M, Horn IR, Cardinale A, et al. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras. Eur J Biochem 2000; 267: 1196-205.
31. Cardinale A, Filesi I, Vetrugno V, Pocchiari M, Sy MS, Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J Biol Chem 2005; 280: 685-94.
32. Böldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 2007; 11: 54-70.
33. Cardinale A, Filesi I, Mattei S, Biocca S Evidence for proteasome dysfunction in cytotoxicity mediated by anti-Ras intracellular antibodies. Eur J Biochem 2003; 270: 3389-97.
34. Filesi I, Cardinale A, Mattei S, Biocca S. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation. J Neurochem 2007; 101: 1516-26.
35. Cardinale A and Biocca S. Combating protein misfolding and aggregation by intracellular antibodies. Curr Mol Med 2008b; 2008; 8: 2-11.
36. Vetrugno V, Cardinale A, Filesi I, Mattei S, et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. BiochemBiophys Res Commun 2005; 338: 1791-7.
37. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-35.
38. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
39. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. b-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 2005; 168: 863-8.
40. Hayashi I, Takatori S, Urano, et al. Single chain variable fragment against nicastrin inhibits the gamma-secretase activity. J Biol Chem 2009; 284: 27838-47.
41. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995; 46: 15-31.
42. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Roos J, Goedert M. Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
43. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-6.
44. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27: 3338-46.
45. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571-6.
46. Goldberg MS, Lansbury Jr PT. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol 2000; 2: E115-9.
47. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-11.
48. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
49. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002; 277: 48984-92.
50. Emadi S, Liu R, Yuan B, et al. Inhibiting aggregation of alphasynuclein with human single chain antibody fragments. Biochemistry 2004; 43: 2871-8.
51. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alphasynuclein. Mol Ther 2004; 10: 1023-31.
52. Shlyakhtenko LS, Yuan B, Emadi S, Lyubchenko YL, Sierks MR. Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy. Nanomedicine 2007; 3: 192-7.
53. Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci Lett 2009; 459: 16-8.
54. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha synuclein-induced toxicity. J Mol Biol 2007; 368: 1132-44.
55. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-10.
56. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA, Advanced Drug Delivery Reviews 2010; 62: 12-27.
57. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
58. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
59. Jones AR, Shusta EV. Blood brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007; 24: 1759-71.
60. Frank RT, Aboody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain, Biochimica et Biophysica Acta 2011; 1816: 191-8.
61. Srikanth M, Kessler JA. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol 2012; 8: 307-18.
62. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
63. Jain KK. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 2012; 8: 1225-33.
64. Fujita K, Yamaguchi Y, Mori T, et al. Effects of a brainengraftable microglial cell line expressing anti-prion scFv antibodies on survival times of mice infected with scrapie prions. Cell Mol Neurobiol 2011; 31: 999-1008.
65. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64: 614-28.
66. McCown TJ. Adeno-Associated Virus (AAV) Vectors in the CNS. Curr Gene Ther 2011; 11: 181-8.
67. Kaplitt MG., Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-105.
68. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-72.
69. Bakay R, Arvanitakis Z, Tuszynski MH, Potkin S, Bartus R, Bennett D. Analyses of a Phase 1 Clinical Trial of Adenoassociated Virus-Nerve Growth Factor (CERE-110) Gene Therapy in Alzheimer's Disease. Neurosurgery 2007; 61: 216.
70. Harding TC, Dickinson PJ, Roberts BN, et al. Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7-and AAV-8-pseudotyped vectors. Hum. Gene Ther 2006; 17: 807-20.
71. Weinberg MS, Blake BL, Samulski RJ, McCown TJ. The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. Gene Ther 2011; 18: 961-8.
72. Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 2006; 13: 517-27.
73. Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioural performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007; 14: 1065-77.
74. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski, RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 1: 1058-69.
75. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-96.
76. Towne C, Schneider BL, Kieran D, Redmond Jr, DE, Aebischer P. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 2010; 17: 1e146.
77. Kaspar BK. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-42.
78. Fukuchi K, Tahara K, Kim HD. Anti-Ab single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006; 23: 502-11.
79. Levites Y, Jansen K, Smithson LA. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid b, amyloid b40, and amyloid b42 singlechain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 2006; 26: 11923-8.
80. Kou J, Kim H, Pattanayak A, et al. Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. J Alzheimers Dis 2011; 27: 23-38.
81. Sudol KL, Mastrangelo MA, Narrow WC, et al. Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol Ther 2009; 17: 2031-40.
82. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 2010;177: 1422-35.
83. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 2010; 18: 1471-81.
84. Wang YJ, Pollard A, Zhong JH, et al. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 2009; 30: 364-76.
85. Wang YJ, Gao CY, Yang M, et al. Intramuscular delivery of a single chain antibody gene prevents brain A+ deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010; 24: 1281-93.
86. Yang J, Pattanayak A, Song M, et al. Muscle-Directed Anti-A+ Single-Chain Antibody Delivery via AAV1 Reduces Cerebral A+ Load in an Alzheimer's Disease Mouse Model. J Mol Neurosci 2012; Sep 4. [Epub ahead of print].
87. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders, Progress in Neurobiology 2009; 88: 272-85.
88. Muller RH, Keck CM. Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol 2004; 4: 471-83.
89. Fazil M, Shadab, Baboota S, Sahni JK, Ali J. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future, J Drug Target 2012; 20: 97-113.
90. Gavini E, Hegge AB, Rassu G, et al. Nasal administration of Carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 2006;307: 9-15.
91. Bonferoni MC, Giunchedi P, Scalia S, Rossi S, Sandri G, Caramella C. Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS Pharm Sci Tech 2006; 7: 104.
92. Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbon nanotubes as medicine, Adv Drug Delivery Rev 2010; 62: 633-49.
93. Bontha S, Kabanov AV, Bronich TK. Polymer micelles with crosslinked ionic cores for delivery of anticancer drugs. J Control Release 2006; 114: 163-74.
94. Bronich, TK, Bontha S, Shlyakhtenko LS, Bromberg L, Hatton TA, Kabanov AV. Template-assisted synthesis of nanogels from pluronic-modified poly(-acrylic acid). J Drug Target 2006; 14: 357-66.
95. McAllister K, Sazani P, Adam M, et al. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc 2002; 124: 15198-207.
96. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain, Bioconjug Chem 2004; 15: 50-60.
97. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007; 32: 1054-82.
98. Shi N, Zhang W, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i. v. administration. Proc Natl Acad Sci USA 2001; 98: 12754-9.
99. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92.
100. Mora M, Sagrista ML, Trombetta D, Bonina FP, De Pasquale A, Saija A. Design and characterization of liposomes containing longchain N-acylpes for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 2002; 19: 1430-8.
101. Schmidt J, Metselaar JM, Wauben MHM, Toyka, KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-904.
102. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 2004; 24: 1193-204.
103. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3V,5V-diocyanoyl-5-fluoro-2V-deoxyuridine and incorporation into solid lipid nanoparticles, Eur J Pharm Biopharm 2002; 54: 285-90.
104. Marroquin Belaunzaran O, Cordero MI, Setola V, et al. Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool. PLoS One 2011; 6: e18268.